Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19

Curr Pharm Des. 2022;28(12):948-968. doi: 10.2174/1381612827666210701150315.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for the current global pandemic, which first emerged in December 2019. This coronavirus has affected 217 countries worldwide, most of which have enacted non-remedial preventive measures, such as nationwide lockdowns, work from home, travel bans, and social isolation. Pharmacists, doctors, nurses, technologists, and other healthcare professionals have played pivotal roles during this pandemic. Unfortunately, confirmed drugs have not been identified for the treatment of patients with coronavirus disease 2019 (COVID-19) caused by SARSCoV2; however, favipiravir and remdesivir have been reported as promising antiviral drugs. Some vaccines have already been developed, and vaccination is ongoing globally. Various nanotechnologies are currently being developed in many countries for preventing SARS-CoV-2 spread and treating COVID-19 infections. In this article, we present an overview of the COVID-19 pandemic situation and discuss nanotechnology-based approaches and investigational therapeutics for COVID-19.

Keywords: COVID-19; SARS-COV-2; antiviral drugs; immunomodulation; nanotechnology; vaccines.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Communicable Disease Control
  • Humans
  • Nanotechnology
  • Pandemics / prevention & control
  • RNA, Viral
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • RNA, Viral